NEW YORK CITY, NY / ACCESS Newswire / March 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is looking into possible claims for those who bought shares of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ:CORT). Investors who have purchased Corcept securities are invited to find more details and help with the investigation by visiting the firm's website: bgandg.com/CORT.
NEW YORK CITY, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is looking into possible claims for those who bought shares of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ:CORT). Investors who have purchased Corcept securities are invited to find more information and help with the investigation by visiting the firm's website: bgandg.com/CORT.
NEW YORK, March 11, 2025 /PRNewswire/ -- Pomerantz LLP is looking into claims for investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT). Investors are encouraged to reach out to Danielle Peyton at [email protected] or call 646-581-9980, ext.
NEW YORK CITY, NY / ACCESS Newswire / March 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is looking into possible claims for those who bought shares of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ:CORT). Investors who have purchased Corcept securities are invited to find more information and help with the investigation by visiting the firm's website: bgandg.com/CORT.
Pomerantz LLP is looking into claims for investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ:CORT) as of March 9, 2025, in New York City. Investors who are interested should reach out to Danielle Peyton at [email protected] or call 646-581-9980, ext.
CORT's drug for Cushing's syndrome, called Korlym, is boosting their sales. Additionally, the FDA's approval of the NDA for relacorilant is a positive sign for the company.
NEW YORK CITY, NY / ACCESS Newswire / March 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is looking into possible claims for those who bought shares of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ:CORT). Investors who have purchased Corcept securities are invited to find more information and help with the investigation by visiting the firm's website: bgandg.com/CORT.
Pomerantz LLP is looking into claims for investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ:CORT) as of March 5, 2025, in New York City. Investors who are interested should reach out to Danielle Peyton at [email protected] or call 646-581-9980, ext.
NEW YORK, March 3, 2025 /PRNewswire/ -- Pomerantz LLP is looking into claims for investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT). Investors are encouraged to reach out to Danielle Peyton at [email protected] or call 646-581-9980, ext.
NEW YORK CITY, NY / ACCESS Newswire / March 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is looking into possible claims for those who bought shares of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ:CORT). Investors who have purchased Corcept securities are invited to find more information and help with the investigation by visiting the firm's website: bgandg.com/CORT.